The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.
2 Primary · 6 Secondary · Reporting Duration: Week 6
Experimental Treatment
Non-Treatment Group
216 Total Participants · 2 Treatment Groups
Primary Treatment: NRCT-101SR · Has Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: